AzTrials
AzTrials

Nasal ObstructionAERWAYNCT04277507

Study of the AERin Medical Vivaer® ARC Stylus for Nasal AirWAY Obstruction

A study testing Vivaer Stylus in people with Nasal Obstruction, run by Aerin Medical at 10 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Post-market study to continue to evaluate the effectiveness of the Vivaer® ARC Stylus for nasal airway obstruction Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Nasal Obstruction
What is being tested?
Vivaer Stylus
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
122 participants
Where
10 sitesUnited States
Study dates
7 Feb 2020to 11 Oct 2024
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age 18 or older
  • Willing and able to provide informed consent
  • Willing and able to comply with the study protocol
  • Seeking treatment for nasal obstruction
  • NOSE score of ≥ 60 at Baseline
  • Nasal valve is a primary or significant contributor to the subject's nasal obstruction as determined by the study investigator (based on clinical presentation, physical examination, nasal endoscopy, etc.) and the subject has a positive response to any of the following temporary measures (based on patient history or office exam):
Show all 10Show fewer
  • Use of external nasal dilator strips (e.g., Breathe Right Strips)
  • Q-Tip test (manual intranasal lateralization)
  • Use of nasal stents
  • Cottle Maneuver (manual lateral retraction of the cheek)

Who cannot join

  • Prior surgical treatment of the nasal valve
  • Rhinoplasty, septoplasty, inferior turbinate reduction or other surgical nasal procedures within the past three (3) months
  • Anatomy that requires an adjunctive surgical nasal procedure on the same day or 3 months after the Vivaer procedure
  • Medical conditions which in the opinion of the treating physician would predispose the subject to poor wound healing or increased surgical risk.

Trial locations and contacts

10 sites in 1 country.

10 sites in 1 country

United States10 sites
  • Baton Rouge General / Sinus and Nasal Specialists of Louisiana

    Baton Rouge, Louisiana, 70809

  • Alabama Nasal and Sinus Center

    Birmingham, Alabama, 35242

  • ENT Associates of South Florida

    Boca Raton, Florida, 33487

  • Chicago Nasal and Sinus Center

    Chicago, Illinois, 60602

  • Arizona Desert ENT Specialists

    Goodyear, Arizona, 85395

  • UT Physicians Otorhinolaryngology - Texas Medical Center

    Houston, Texas, 77030

  • ENT Associates of Texas

    McKinney, Texas, 75070

  • Advocare Aroesty ENT Associates

    Mount Arlington, New Jersey, 07856

  • ENT Associates of South Florida

    Plantation, Florida, 33324

  • Sacramento ENT

    Roseville, California, 95661

Other trials in United States

About this study

Official title: A Prospective, Multicenter Study of the AERin Medical Vivaer® ARC Stylus for Nasal AirWAY Obstruction (AERWAY)

Post-market study to continue to evaluate the effectiveness of the Vivaer® ARC Stylus for nasal airway obstruction

Read the detailed description

Prospective, Multicenter, Non-randomized Study of the Aerin Medical Vivaer® ARC Stylus for Nasal Airway Obstruction to continue to evaluate the effectiveness of the Vivaer® ARC Stylus for treating the nasal valve area to improve symptoms in those diagnosed with nasal airway obstruction.

Being tested
Vivaer Stylus
Keywords
Nasal valve, Nasal airway obstruction
Medical subject headings
Nasal Obstruction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Vivaer StylusDevice

    Also called Aerin Medical Device

    Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area

Study groups in NCT04277507
Study groupRoleWhat they receive
Vivaer StylusExperimentalIntervention: Procedure: thermal treatment of submucosal tissue including cartilage in the internal nasal valve area
Receives: Device: Vivaer Stylus

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Nasal Obstructive Symptom Evaluation (NOSE) Scores From Baseline to 3 Months

    Mean change in NOSE score from Baseline to 3 months.Scores may range from the best score of 0, meaning no nasal obstructive symptoms to the worst score of 100, meaning severe nasal obstructive symptoms.

    Measured: 3 Month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Feb 2020
  2. Study start7 Feb 2020
  3. Primary completion31 Dec 2020
  4. Study completion11 Oct 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
122 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04277507
Sponsor's protocol ID
TP900
Acronym
AERWAY
Status last verified
Oct 2026
First submitted
17 Feb 2020
Last updated
2 Nov 2026
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Publications

  • Yao WC, Pritikin J, Sillers MJ, Barham HP. Two-year outcomes of temperature-controlled radiofrequency device treatment of the nasal valve for patients with nasal airway obstruction. Laryngoscope Investig Otolaryngol. 2023 Jun 15;8(4):808-815. doi: 10.1002/lio2.1089. eCollection 2023 Aug.

    PubMed 37621275
  • Yao WC, Ow RA, Barham HP (2021) Temperature-Controlled Radiofrequency Treatment of the Nasal Valve and Nasal Airway Obstruction: Early Results of a Prospective, Multi-Center Study. J Otolaryngol Rhinol 7:104. doi.org/10.23937/2572-4193.1510105

  • Yao WC, Ow R, Sillers MJ, Nachlas NE, Johnson CD, Ehmer D, Pritikin J, Barham HP. Three-Year Outcomes After Temperature-Controlled Radiofrequency Treatment of Nasal Airway Obstruction. OTO Open. 2025 Apr 7;9(2):e70111. doi: 10.1002/oto2.70111. eCollection 2025 Apr-Jun.

    PubMed 40196218

Questions about this trial

What is this clinical trial studying?

A study testing Vivaer Stylus in people with Nasal Obstruction, run by Aerin Medical at 10 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 10 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 25 May 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Nasal Obstructive Symptom Evaluation (NOSE) Scores From Baseline to 3 Months (time frame: 3 Month). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04277507, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in